AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tyra Biosciences, Inc. Director's Dealing 2021

Nov 5, 2021

32575_dirs_2021-11-04_c6a0e022-63eb-4b1d-ad05-d704bc2e0539.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tyra Biosciences, Inc. (TYRA)
CIK: 0001863127
Period of Report: 2021-11-02

Reporting Person: Tada Hiroomi (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-02	Stock Option (Right to Buy)	$24.15	A	83626	Acquired	2031-11-01	Common Stock (83626)	Direct
2021-11-02	Stock Option (Right to Buy)	$24.15	A	7964	Acquired	2031-11-01	Common Stock (7964)	Direct
2021-11-02	Stock Option (Right to Buy)	$24.15	A	7964	Acquired	2031-11-01	Common Stock (7964)	Direct

Footnotes

F1: 1/48th of the shares subject to the option vest monthly following November 2, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

F2: The option vests based on achievement of a performance objective.